These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35150730)

  • 1. Special Issue on new therapeutic approaches to Parkinson disease.
    Fox SH; Brotchie JM
    Neuropharmacology; 2022 May; 208():108998. PubMed ID: 35150730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Vesicles in the Treatment of Parkinson's Disease: A Review.
    Yang X; Ma Y; Xie H; Dong S; Rao G; Yang Z; Zhang J; Wu Q
    Curr Med Chem; 2021; 28(31):6375-6394. PubMed ID: 33441061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
    Szabó N; Kincses ZT; Vécsei L
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging preclinical pharmacological targets for Parkinson's disease.
    More SV; Choi DK
    Oncotarget; 2016 May; 7(20):29835-63. PubMed ID: 26988916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: emerging pharmacotherapy.
    Strecker K; Schwarz J
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):573-91. PubMed ID: 19046128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to the treatment of Parkinson's Disease.
    Ellis JM; Fell MJ
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4247-4255. PubMed ID: 28869077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Stage-Based Approach to Therapy in Parkinson's Disease.
    Carrarini C; Russo M; Dono F; Di Pietro M; Rispoli MG; Di Stefano V; Ferri L; Barbone F; Vitale M; Thomas A; Sensi SL; Onofrj M; Bonanni L
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31434341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies.
    Karthivashan G; Ganesan P; Park SY; Lee HW; Choi DK
    Biomaterials; 2020 Feb; 232():119704. PubMed ID: 31901690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Older Parkinson's Disease.
    Lenka A; Padmakumar C; Pal PK
    Int Rev Neurobiol; 2017; 132():381-405. PubMed ID: 28554416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Pharmacotherapies for Motor Symptoms in Parkinson's Disease.
    Majali MA; Sunnaa M; Chand P
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):263-273. PubMed ID: 34219526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy: a viable therapeutic strategy for Parkinson's disease?
    Berry AL; Foltynie T
    J Neurol; 2011 Feb; 258(2):179-88. PubMed ID: 20963433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of pain in the pharmacological management of Parkinson's disease.
    Jost WH; Buhmann C
    Expert Opin Pharmacother; 2019 Oct; 20(15):1847-1854. PubMed ID: 31290336
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.